The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N06 | Psychoanaleptics | |
| 3 | N06D | Anti-dementia drugs | |
| 4 | N06DA | Anticholinesterases | |
| 5 | N06DA04 | Galantamine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 16 mg |
| Active Ingredient | Description | |
|---|---|---|
| Galantamine |
Galantamine, a tertiary alkaloid is a selective, competitive and reversible inhibitor of acetylcholinesterase. In addition, galantamine enhances the intrinsic action of acetylcholine on nicotinic receptors, probably through binding to an allosteric site of the receptor. As a consequence, an increased activity in the cholinergic system associated with improved cognitive function can be achieved in patients with dementia of the Alzheimer type. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CONSION XL Prolonged-release capsule, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| GALSYA Prolonged-release capsule, hard | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
